Innoviva, Inc. (INVA) |
|
12.8 -0.16 (-1.23%)
|
02-03 16:00 |
|
Open: |
12.95 |
Pre. Close: |
12.96 |
|
High:
|
13.1 |
Low:
|
12.74 |
|
Volume:
|
546,580 |
Market Cap:
|
893(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 3:48:27 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 15.35  One year: 16.11 |
| Support: |
Support1: 12.1 Support2: 10.06 |
| Resistance: |
Resistance1: 13.15 Resistance2: 13.8 |
| Pivot: |
12.85 |
| Moving Average: |
MA(5): 12.75  MA(20): 12.98
MA(100): 12.97 MA(250): 14.91 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 43.8 %D(3): 38.9 |
| RSI: |
RSI(14): 46.9 |
| 52-week: |
High: 20.7 Low: 11.56 |
| Average Vol(K): |
3-Month: 597 (K) 10-Days: 531 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INVA ] has closed above bottom band by 47.5%. Bollinger Bands are 6.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
13.04 - 13.09 |
13.09 - 13.14 |
|
Low:
|
12.6 - 12.66 |
12.66 - 12.72 |
|
Close:
|
12.86 - 12.96 |
12.96 - 13.05 |
|
Company Description |
|
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. |
Headline News |
Fri, 03 Feb 2023
Great West Life Assurance Co. Can Invests $799000 in Innoviva, Inc ... - MarketBeat
Thu, 02 Feb 2023
Westfield Capital Management Co Increases Position in Innoviva ... - Nasdaq
Thu, 02 Feb 2023
Russia's Role As Arms Exporter Likely Undermined By Its Inva... - MENAFN.COM
Thu, 26 Jan 2023
DekaBank Deutsche Girozentrale Sells 17115 Shares of Innoviva ... - MarketBeat
Mon, 23 Jan 2023
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds - Yahoo Finance
Fri, 20 Jan 2023
Assetmark Inc. Reduces Stake in Innoviva, Inc. (NASDAQ:INVA) - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
70 (M) |
| Shares Float |
58 (M) |
|
% Held by Insiders
|
0.8 (%) |
|
% Held by Institutions
|
113.3 (%) |
|
Shares Short
|
9,440 (K) |
|
Shares Short P.Month
|
10,240 (K) |
Stock Financials |
|
EPS
|
3.38 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
9.18 |
|
Profit Margin (%)
|
78.3 |
|
Operating Margin (%)
|
77.8 |
|
Return on Assets (ttm)
|
16.3 |
|
Return on Equity (ttm)
|
58.9 |
|
Qtrly Rev. Growth
|
-31.3 |
|
Gross Profit (p.s.)
|
5.6 |
|
Sales Per Share
|
5.34 |
|
EBITDA (p.s.)
|
4.19 |
|
Qtrly Earnings Growth
|
211.1 |
|
Operating Cash Flow
|
291 (M) |
|
Levered Free Cash Flow
|
210 (M) |
Stock Valuations |
|
PE Ratio
|
3.79 |
|
PEG Ratio
|
0.1 |
|
Price to Book value
|
1.39 |
|
Price to Sales
|
2.39 |
|
Price to Cash Flow
|
3.07 |
Stock Dividends |
|
Dividend
|
0.25 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
1.9% |
|
Dividend Pay Date
|
2015-09-29 |
|
Ex-Dividend Date
|
2015-09-07 |
|
Your Ad Here
|
|
